Ken J. Bulpitt, MD; Philip J. Clements, MD; Peter A. Lachenbruch, PhD; Harold E. Paulus, MD; James B. Peter, MD, PhD; Mel S. Agopian, MS; Joyce Z. Singer, MD; Virginia D. Steen, MD; Daniel O. Clegg, MD; Carol M. Ziminski, MD; Graciela S. Alarcon, MD, MPH; Michael E. Luggen, MD; Richard P. Polisson, MD; Robert F. Willkens, MD; James C. Reading, PhD; H. James Williams, MD; John R. Ward, MD
To characterize the course of early scleroderma and to delineate prognostic factors present within 1 year of disease onset that might identify patients at high risk.
Inception cohort study.
Ten university-based rheumatology clinics participating in the Cooperative Systematic Studies of Rheumatic Diseases Program.
Forty-eight patients who had had scleroderma for less than 1 year.
Fifteen patients with early scleroderma who died were compared with those still living during the initial study period (1982 to 1992). Kaplan-Meier survival estimation and Cox proportional-hazards analysis were used to analyze baseline variables for their ability to predict survival duration.
Eight of 15 deaths were due to cardiac or pulmonary system failure. The estimated 5-year survival rate was 68%. Baseline factors that were the most predictive of a poor outcome included the presence of abnormal cardiopulmonary signs and abnormal urine sediment (pyuria, hematuria).
Evidence of early cardiopulmonary disease, renal disease, inflammation, or immune activation may identify a subset of patients with scleroderma who will experience rapidly progressive disease and early death.
Bulpitt KJ, Clements PJ, Lachenbruch PA, Paulus HE, Peter JB, Agopian MS, et al. Early Undifferentiated Connective Tissue Disease: III. Outcome and Prognostic Indicators in Early Scleroderma (Systemic Sclerosis). Ann Intern Med. ;118:602–609. doi: 10.7326/0003-4819-118-8-199304150-00005
Download citation file:
Published: Ann Intern Med. 1993;118(8):602-609.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use